Integrated approaches to therapeutic target gene discovery

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 683-689

  DeFife, Kristin M ^a   Wong Staal, Flossie ^a  

^a Immusol Inc   (United States)

Author keywords

Druggable targets; Genomics; Inverse Genomics ; Proteomics; Systems biology

Indexed keywords

DNA MICROARRAY; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENOMICS; HUMAN; NONHUMAN; PROTEOMICS; REVIEW; TWO HYBRID SYSTEM;

ANIMALS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETICS, MEDICAL; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS;

EID: 0036771226     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Drews J: Drug discovery: A historical perspective. Science (2000) 287:1960-1964.
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD et al: The sequence of the human genome. Science (2001) 291:1304-1351.
3. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R: Initial sequencing and analysis of the human genome. Nature (2001) 409:860-921.
4. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet (1999) 23:41-46.
5. Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML, Kallioniemi A: Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA (2001) 98:5711-5716.
6. Yeakley JM, Fan JB, Doucet D, Luo L, Wickham E, Ye Z, Chee MS, Fu XD: Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol (2002) 20:353-358.
7. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannell B, Allard J, Klonowski P et al: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med (2002) 8:500-508. This is the first study to describe expression differences between different stages of MS lesions and identified new targets, which could help tailor therapies for distinct stages of MS.
8. Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, Xiao H, Rogers KE, Wan JS, Jackson MR, Eflander MG: Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med (1999) 5:117-122.
9. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA et al: Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol (2002) 20:387-392. This report addresses the difficult problem of measuring expression from rare cells, and explains the development of a PCR-based technique to analysis gene expression in single cells.
10. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science (1995) 270:484-487.
11. Menssen A, Hermeking H: Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA (2002) 99:6274-6279.
12. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler KW, Velculescu VE: Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 20:508-512.The modified SAGE method, longSAGE, is developed and used to demonstrate the shortfalls of relying on bioinformatics gene predictions to estimate the number of genes, and therefore tractable drug targets, in the genome.
13. Harrington JJ, Sherf B, Rundlett S, Jackson PD, Perry R, Cain S, Leventhal C, Thornton M, Ramachandran R, Whittington J, Lerner L et al: Creation of genome-wide protein expression libraries using random activation of gene expression. Nat Biotechnol (2001) 19:440-445. An elegant method is described that can be used to identify and characterize genes, as well as screen for a protein of interest.
14. Welch PJ, Marcusson EG, Li QX, Beger C, Kruger M, Zhou C, Leavitt M, Wong-Staal F, Barber JR: Identification and validation of a gene involved in anchorage-independent cell growth control using a library of randomized hairpin ribozymes. Genomics (2000) 66:274-283.
15. Krüger M, Beger C, Welch PJ, Barber JR, Manns MP, Wong- Staal F: Involvement of proteasome α-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol Cell Biol (2001) 21:8357-8364.
16. Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F: Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA (2001) 98:130-135.
17. Pagliuca A, Bartoli PC, Saccone S, Della Valle G, Lania L: Molecular cloning of ID4, a novel dominant negative helix-loop-helix human gene on chromosome 6p21.3-p22. Genomics (1995) 27:200-203.
18. Abbott A: Workshop prepares ground for human proteome project. Nature (2001) 413:763.
19. Uetz P, Giot L, Cagney G, Mansfield TA, Judson RS, Knight JR, Lockshon D, Narayan V, Srinivasan M, Pochart P, Qureshi-Emili A et al: A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature (2000) 403:623-627.
20. Ito T, Chiba T, Ozawa R, Yoshida M, Hattori M, Sakaki Y: A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc Natl Acad Sci USA (2001) 98:4569-4574.
21. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M et al: Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 415:141-147.
22. Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL, Millar A, Taylor P, Bennett K, Boutilier K, Yang L et al: Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 415:180-183.
23. O'Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, Watson SP, Hebestreit HF: Towards complete analysis of the platelet proteome. Proteomics (2002) 2:288-305.
24. Mitchell P: A perspective on protein microarrays. Nat Biotechnol (2002) 20:225-229.
25. MacBeath G, Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science (2000) 289:1760-1763.
26. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, Lan N, Jansen R, Bidlingmaier S, Houfek T, Mitchell T et al: Global analysis of protein activities using proteome chips. Science (2001) 293:2101-2105. This study gives credence to the power of protein chips for drug discovery, through the elucidation of whole proteome interactions in yeast.
27. Wang D, Liu S, Trummer BJ, Deng C, Wang A: Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. Nat Biotechnol (2002) 20:275-281.
28. Houseman BT, Huh JH, Kron SJ, Mrksich M: Peptide chips for the quantitative evaluation of protein kinase activity. Nat Biotechnol (2002) 20:270-274.
29. Ziauddin J, Sabatini DM: Microarrays of cells expressing defined cDNAs. Nature (2001) 411:107-110. This paper describes the creation of a derivative of conventional protein chips, which may have a strong impact on the use of proteomics for target gene identification.
30. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin III EF, Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 20:1981-1989. This paper describes the design and utility of a novel protein array that is broadly applicable to high-throughput analysis of differential protein expression.
31. Omstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF 3rd, Emmert-Buck MR: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis (2000) 21:2235-2242.
32. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF 3rd: New approaches to proteomic analysis of breast cancer. Proteomics (2001) 1:1205-1215.
33. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 2:76-84. New and older techniques are combined for powefful identification and validation of potential therapeutic targets.
34. Tong AH, Drees B, Nardelli G, Bader GD, Brannetti B, Castagnoli L, Evangelista M, Ferracuti S, Nelson B, Paoluzi S, Quondam M et al: A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules. Science (2002) 295:321-324. This work describes novel uses for phage display and yeast two-hybrid techniques, and demonstrates the move towards systems biology.
35. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, Bumgamer R, Goodlett DR, Aebersold R, Hood L: Integrated genomic and proteomic analysis of a systematically perturbed metabolic network. Science (2001) 292:929-934.
36. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, Dean NM: Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol (2000) 18:862-867.
37. Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM, Levin AA: Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther (2001) 296:388-395.
38. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498. This seminal work demonstrated sequence-specific gene inactivation in mammalian cells by small siRNA duplexes.
39. Kallioniemi OP, Wagner U, Kononen J, Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet (2001) 10:657-662.
40. Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Comelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W et al: Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res (2002) 62:1256-1260. Methodological integration of an in vivo model and tissue microarrays of clinical samples to validate gene targets in prostate cancer progression.
41. Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ: Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science (2001) 291:2613-2616. An important demonstration of the use of genetically engineered mice to promote a gene to the status of a tractable drug target.
42. Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A: In vivo drug target discovery: Identifying the best targets from the genome. Curr Opin Biotechnol (2001) 12:626-631.
43. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, Mullins JJ: Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem (2001) 276:36727-36733.